The information contained in this section of Ascelia Pharma AB’s (“Ascelia Pharma”) website is restricted and may not be accessed by residents of certain countries based on applicable securities law regulations.
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, WHOLLY OR PARTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW.
This website and the information contained herein is not intended for, and may not be accessed by, or distributed or disseminated to, persons resident or physically present in the United States of America (the ”United States”), Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa or South Korea and do not constitute an offer to exercise warrants series TO 1 for subscription of ordinary shares in Ascelia Pharma in any of the above-mentioned jurisdictions or in any other jurisdiction in which such offer or solicitation would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The securities of Ascelia Pharma referred to on this website have not been, and will not be, registered under the Securities Act of 1933, as amended (the ”Securities Act”), and may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act.
All persons residing outside of the above-mentioned jurisdictions who wish to access the documents contained on this website should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this website, or require registration or approval for the exercise of warrants series TO 1 for subscription of ordinary shares in Ascelia Pharma. It is noted that the invitation to the persons concerned to subscribe for units consisting of ordinary shares and warrants series TO 1 in Ascelia Pharma only has been made through the prospectus published by Ascelia Pharma on 16 August 2024, which has been approved and registered by the Swedish Financial Supervisory Authority. Ascelia Pharma assumes no responsibility if there is a violation of applicable law and regulations by any person.
If you are not permitted to view materials on this website or are in any doubt as to whether you are permitted to view these materials, please exit this website.
By clicking ”Confirm” you confirm and certify that:
- You are not a resident of or physically present in any of the above jurisdictions or any other restricted jurisdiction; and
- you are either:
- a resident of, or physically present in, Sweden;
- if resident or physically present in a Member State of the European Economic Area other than Sweden, a qualified investor as defined in Regulation (EU) 2017/1129 of the European parliament and of the council; or
- otherwise authorized to access this information pursuant to applicable laws or regulations.